- European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
- Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties
- Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference
- Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity
- Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML
- Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
- Moleculin Reports Full Year 2023 Financial Results
- Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast
- Moleculin Announces Reverse Stock Split
- Moleculin to Present at the 36th Annual ROTH Conference
More ▼
Key statistics
On Friday, Moleculin Biotech Inc (MBRX:NAQ) closed at 4.65, 8.64% above its 52-week low of 4.28, set on Apr 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.59 |
---|---|
High | 4.66 |
Low | 4.40 |
Bid | 4.32 |
Offer | 4.84 |
Previous close | 4.52 |
Average volume | 25.94k |
---|---|
Shares outstanding | 2.23m |
Free float | 2.12m |
P/E (TTM) | -- |
Market cap | 10.08m USD |
EPS (TTM) | -15.06 USD |
Data delayed at least 15 minutes, as of Apr 19 2024 21:00 BST.
More ▼